オンコリティックウイルス療法市場- 世界の産業規模、シェア、動向、機会、予測、ウイルスタイプ別、用途別、エンドユーザー別、地域別セグメント、競合、2020年～2030年

世界のオンコリティックウイルス療法市場は、2024年に165億7,000万米ドルと評価され、予測期間中のCAGRは22.92%で、2030年には571億5,000万米ドルに達すると予測されています。

オンコリティックウイルスは、がん細胞に感染して選択的に複製し、がん細胞を破壊したり、プログラムされた細胞死（アポトーシス）を引き起こしたりすることができるウイルスの一種です。これらのウイルスは、腫瘍選択的嗜好性を示すように操作されたもの、あるいは自然発生したものです。つまり、正常で健康な細胞を免れる一方で、がん細胞を標的として複製する生得的な能力を有しています。オンコリティックウイルスは、標的を絞った革新的な治療法としての可能性から、がん治療の分野で注目され、重要視されています。がん細胞溶解性ウイルスは、がん細胞内に感染し複製することを好む性質を持っています。この選択性は多くの場合、がん細胞と健常細胞との細胞因子や分子特性の違いに基づいています。がん細胞内に入ると、オンコリティックウイルスは複製・増殖します。この複製は最終的にがん細胞の溶解（破裂）につながり、新たに形成されたウイルス粒子を放出し、隣接するがん細胞に感染します。このプロセスは続き、腫瘍全体に感染を効果的に広げます。

継続的な研究開発により、オンコリティックウイルスに対する理解が深まり、より強力で標的を絞った治療法の開発につながっています。このような科学的進歩が、この分野の技術革新を後押ししています。様々ながん種に対するオンコリティックウイルス療法の臨床試験や実臨床での応用において良好な結果が得られたことで、その有効性に対する信頼が高まっています。患者の生存利益と転帰の改善を実証することが、重要な推進力となっています。オンコリティックウイルス療法を免疫療法や標的治療などの他の治療法と組み合わせるというコンセプトが支持されています。このような併用療法は、がん治療成績向上の可能性を高めるものです。オンコリティックウイルス療法に関するヘルスケア専門家、患者、一般市民の認識と教育の高まりが、その受容と採用に寄与しています。

主な市場促進要因

調査の進歩

主な市場課題

有効性と安全性への懸念

主要市場動向

多様なウイルスプラットフォーム

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のオンコリティックウイルス療法市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • ウイルスタイプ別（アデノウイルス、単純ヘルペスウイルス（HSV）、麻疹ウイルス、レオウイルス、ワクシニアウイルス、水疱性口内炎ウイルス（VSV）、その他）
  • 用途別（固形腫瘍、造血悪性腫瘍）
  • エンドユーザー別（病院、がん調査機関、バイオ医薬品企業）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 アジア太平洋地域のオンコリティックウイルス療法市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州のオンコリティックウイルス療法市場展望

• 市場規模・予測
• 市場シェア・予測
• 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米のオンコリティックウイルス療法市場展望

• 市場規模・予測
• 市場シェア・予測
• 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米のオンコリティックウイルス療法市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのオンコリティックウイルス療法市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界のオンコリティックウイルス療法市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 PESTEL分析

第16章 競合情勢

• Amgen Inc.
• Merck & Co., Inc.
• Oncolytics Biotech Inc
• PsiOxus Therapeutics Ltd.
• Vyriad, Inc.
• Cold Genesys Inc.
• Sorrento Therapeutics, Inc.
• Takara Bio Inc.
• Replimune Group Inc.
• Genelux Corporation

第17章 戦略的提言

第18章 調査会社について・免責事項

Global Oncolytic Virus Therapy Market was valued at USD 16.57 billion in 2024 and is expected to reach USD 57.15 billion by 2030 with a CAGR of 22.92% during the forecast period. Oncolytic viruses are a class of viruses that can infect and selectively replicate in cancer cells, leading to their destruction or causing them to undergo programmed cell death (apoptosis). These viruses are engineered or naturally occurring to exhibit a tumor-selective preference, meaning they have an innate ability to target and replicate within cancerous cells while sparing normal, healthy cells. Oncolytic viruses have gained attention and significance in the field of cancer therapy due to their potential as a targeted and innovative treatment approach. Oncolytic viruses have an inherent preference for infecting and replicating within cancer cells. This selectivity is often based on differences in cellular factors and molecular characteristics between cancer cells and healthy cells. Once inside cancer cells, oncolytic viruses replicate and multiply. This replication eventually leads to the lysis (bursting) of the cancer cell, releasing newly formed viral particles that can infect adjacent cancer cells. This process continues, effectively spreading the infection throughout the tumor.

Ongoing research has deepened our understanding of oncolytic viruses, leading to the development of more potent and targeted therapies. This scientific progress drives innovation in the field. Positive outcomes in clinical trials and real-world applications of oncolytic virus therapies for various cancer types have boosted confidence in their efficacy. Demonstrating survival benefits and improved outcomes for patients has been a key driver. The concept of combining oncolytic virus therapy with other treatment modalities, such as immunotherapies or targeted therapies, has gained traction. This combination approach enhances the potential for better cancer treatment outcomes. Increased awareness and education about oncolytic virus therapy among healthcare professionals, patients, and the public have contributed to its acceptance and adoption.

Key Market Drivers

Advancements in Research

Researchers have made significant progress in genetically engineering oncolytic viruses to enhance their tumor-selectivity and therapeutic effectiveness. This includes modifying the virus's ability to replicate in cancer cells while sparing healthy cells. Combining oncolytic virus therapy with other cancer treatments, such as immunotherapies (e.g., immune checkpoint inhibitors) and targeted therapies, has shown promise in improving overall treatment outcomes. Researchers are exploring the best combinations and treatment sequences. Research efforts have led to the development of safer oncolytic viruses with reduced potential for off-target effects. Safety is a critical consideration in regulatory approval and clinical use. The human immune system can neutralize oncolytic viruses. Researchers are developing strategies to evade the host immune response or to enhance the immunostimulatory effects of oncolytic viruses, making them more effective in combating cancer.

Identifying biomarkers that can predict a patient's response to oncolytic virus therapy is a key area of research. This enables a more personalized approach to treatment and ensures that therapy is administered to those who are most likely to benefit. Research has led to innovations in the delivery of oncolytic viruses to tumor sites. This includes the use of nanoparticles, viral vectors, and specialized delivery vehicles to enhance the efficiency of virus delivery. While the Herpes Simplex Virus (HSV) has been prominent, research has expanded to include other virus platforms, such as adenoviruses, reoviruses, and poxviruses. Exploring a variety of virus platforms broadens the scope of oncolytic virus therapy. Ongoing clinical trials have explored the use of oncolytic virus therapy in various cancer types and at different stages of disease. These trials provide valuable data on safety and efficacy, helping to refine treatment protocols.

Key Market Challenges

Efficacy and Safety Concerns

Efficacy can vary among different patients and cancer types. Not all patients respond equally to oncolytic virus therapy, and identifying predictors of response is an ongoing challenge. Tumors are biologically diverse, and this heterogeneity can affect the ability of oncolytic viruses to target and destroy cancer cells effectively. Adapting therapies to address tumor heterogeneity remains a challenge. The tumor microenvironment can be immunosuppressive, hindering the immune system's response to oncolytic viruses. Strategies to overcome immunosuppression are under investigation. Ensuring that oncolytic viruses specifically target cancer cells while sparing healthy tissue is a safety concern. Reducing off-target effects and minimizing collateral damage is a research priority. Tumors can develop resistance to oncolytic virus therapy over time, limiting its long-term effectiveness. Understanding and mitigating resistance mechanisms is a complex challenge. Safety concerns arise from the potential for oncolytic viruses to cause adverse events. Balancing the need for a potent antitumor effect with acceptable safety profiles is a delicate balance.

Key Market Trends

Diverse Virus Platforms

Different virus platforms have unique mechanisms of tumor selectivity, replication kinetics, and host interactions. Researchers are studying these properties to optimize each platform for specific cancer types and patient populations. Combining different virus platforms with one another or with other cancer treatments, such as immunotherapies or targeted therapies, is a growing trend. These combinations offer the potential for enhanced therapeutic effects and expanded applications. The diversity of virus platforms allows for a more personalized approach to treatment. By selecting the most suitable virus platform based on a patient's cancer characteristics, oncolytic virus therapy can be tailored to individual needs. The use of diverse virus platforms can help overcome challenges related to resistance mechanisms that tumors may develop against a particular virus. By switching to a different virus platform, clinicians can potentially re-sensitize the tumor to therapy. Different virus platforms come with varying safety profiles. Researchers aim to identify platforms that minimize off-target effects and adverse events while maximizing antitumor effects. The choice of virus platform can influence the method of delivery, such as intratumoral injection, intravenous administration, or targeted delivery systems. These strategies are designed to enhance virus distribution and tumor penetration.

Key Market Players

• Amgen Inc.
• Merck & Co., Inc.
• Oncolytics Biotech Inc.
• PsiOxus Therapeutics Ltd.
• Vyriad, Inc.
• SillaJen Biotherapeutics
• Cold Genesys Inc.
• Sorrento Therapeutics, Inc.
• Takara Bio Inc.
• Replimune Group Inc.
• Genelux Corporation

Report Scope:

In this report, the Global Oncolytic Virus Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oncolytic Virus Therapy Market, By Virus Type:

• Adenovirus
• Herpes Simplex Virus (HSV)
• Measles Virus
• Reovirus
• Vaccinia Virus
• Vesicular Stomatitis Virus (VSV)
• Others

Oncolytic Virus Therapy Market, By Application:

• Solid Tumors
• Hematological Malignancies

Oncolytic Virus Therapy Market, By End-User:

• Hospitals
• Cancer Research Institutes
• Biopharmaceutical Companies

Oncolytic Virus Therapy Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Oncolytic Virus Therapy Market.

Available Customizations:

Global Oncolytic Virus Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Applications
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oncolytic Virus Therapy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Virus Type (Adenovirus, Herpes Simplex Virus (HSV), Measles Virus, Reovirus, Vaccinia Virus, Vesicular Stomatitis Virus (VSV), Others)
  • 5.2.2. By Application (Solid Tumors, Hematological Malignancies)
  • 5.2.3. By End User (Hospitals, Cancer Research Institutes, Biopharmaceutical Companies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Oncolytic Virus Therapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Virus Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Oncolytic Virus Therapy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Virus Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. India Oncolytic Virus Therapy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Virus Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Australia Oncolytic Virus Therapy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Virus Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User
  • 6.3.4. Japan Oncolytic Virus Therapy Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Virus Type
      • 6.3.4.2.2. By Application
      • 6.3.4.2.3. By End User
  • 6.3.5. South Korea Oncolytic Virus Therapy Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Virus Type
      • 6.3.5.2.2. By Application
      • 6.3.5.2.3. By End User

7. Europe Oncolytic Virus Therapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Virus Type
  • 7.2.2. By Application
  • 7.2.3. By End User
• 7.2.4 By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Oncolytic Virus Therapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Virus Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Oncolytic Virus Therapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Virus Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. Spain Oncolytic Virus Therapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Virus Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Oncolytic Virus Therapy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Virus Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. United Kingdom Oncolytic Virus Therapy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Virus Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. North America Oncolytic Virus Therapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Virus Type
  • 8.2.2. By Application
  • 8.2.3. By End User
• 8.2.4 By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Oncolytic Virus Therapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Virus Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. Mexico Oncolytic Virus Therapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Virus Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Canada Oncolytic Virus Therapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Virus Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User

9. South America Oncolytic Virus Therapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Virus Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Oncolytic Virus Therapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Virus Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Oncolytic Virus Therapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Virus Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Oncolytic Virus Therapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Virus Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Middle East and Africa Oncolytic Virus Therapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Virus Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Oncolytic Virus Therapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Virus Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Oncolytic Virus Therapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Virus Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Oncolytic Virus Therapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Virus Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Oncolytic Virus Therapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Amgen Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. Merck & Co., Inc.
• 16.3. Oncolytics Biotech Inc
• 16.4. PsiOxus Therapeutics Ltd.
• 16.5. Vyriad, Inc.
• 16.6. Cold Genesys Inc.
• 16.7. Sorrento Therapeutics, Inc.
• 16.8. Takara Bio Inc.
• 16.9. Replimune Group Inc.
• 16.10. Genelux Corporation

17. Strategic Recommendations

18. About Us & Disclaimer